Literature DB >> 19025401

Chemical modification of siRNAs for in vivo use.

Mark A Behlke1.   

Abstract

Well over a hundred reports have been published describing use of synthetic small-interfering RNAs (siRNAs) in animals. The majority of these reports employed unmodified RNA duplexes. While unmodified RNA is the natural effector molecule of RNA interference, certain problems arise with experimental or therapeutic use of RNA duplexes in vivo, some of which can be improved or solved through use of chemical modifications. Judicious use of chemical modifications can improve the nuclease stability of an RNA duplex, decrease the likelihood of triggering an innate immune response, lower the incidence of off-target effects (OTEs), and improve pharmacodynamics. This review will examine studies that document the utility of various chemical modifications for use in siRNAs, both in vitro and in vivo, with close attention given to reports demonstrating actual performance in animal model systems.

Mesh:

Substances:

Year:  2008        PMID: 19025401     DOI: 10.1089/oli.2008.0164

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  155 in total

1.  Dual-targeting siRNAs.

Authors:  Katrin Tiemann; Britta Höhn; Ali Ehsani; Stephen J Forman; John J Rossi; Pål Saetrom
Journal:  RNA       Date:  2010-04-21       Impact factor: 4.942

Review 2.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 3.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

Review 4.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

Review 5.  Non-natural nucleic acids for synthetic biology.

Authors:  Daniel H Appella
Journal:  Curr Opin Chem Biol       Date:  2009-10-29       Impact factor: 8.822

6.  Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.

Authors:  Xiaohua Ni; Yonggang Zhang; Judit Ribas; Wasim H Chowdhury; Mark Castanares; Zhewei Zhang; Marikki Laiho; Theodore L DeWeese; Shawn E Lupold
Journal:  J Clin Invest       Date:  2011-05-09       Impact factor: 14.808

Review 7.  RNAi medicine for the brain: progresses and challenges.

Authors:  Ryan L Boudreau; Edgardo Rodríguez-Lebrón; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

8.  SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation.

Authors:  Shyam Ramachandran; Samantha R Osterhaus; Kalpaj R Parekh; Ashley M Jacobi; Mark A Behlke; Paul B McCray
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 9.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.